摘要
目的由于晚期肺鳞癌的早期症状和体征均不明显,很多患者没有及时确诊及治疗,失去了手术机会,化疗是晚期患者的主要治疗方式,目的是延长生存期,提高生活质量。本研究探讨分析吉西他滨联合奈达铂方案治疗晚期肺鳞癌的临床疗效和安全性。方法选取2015-10-08-2016-12-31海口市人民医院收治的晚期肺鳞癌患者184例,按照随机数字表法将患者分为对照组和观察组各92例。对照组患者接受多西他赛联合顺铂的化疗方案,观察组患者接受吉西他滨联合奈达铂的治疗方案。在患者接受2个周期治疗后评估治疗的近期疗效和不良反应发生情况,并进行两组间比较。结果两组患者的近期疗效比较,差异无统计学意义,χ~2=0.113,P=0.945。观察组和对照组总缓解率分别为40.22%(37/92)和39.13%(32/92),差异无统计学意义,χ~2=0.023,P=0.880;观察组和对照组疾病控制率分别为65.22%(60/92)和66.30%(61/92),差异无统计学意义,χ~2=0.024,P=0.877。两组患者化疗期间不良反应比较,观察组患者白细胞下降(χ~2=31.745,P<0.001)、红细胞下降(χ~2=11.280,P=0.001)和恶心呕吐(χ~2=11.290,P=0.001)的发生率显著小于对照组,差异均有统计学意义。但两组患者血小板下降(χ~2=0.035,P=0.851)、肝功能受损(χ~2=2.421,P=0.120)、肾功能受损(χ~2=0.464,P=0.496)和脱发(χ~2=1.517,P=0.218)的发生率差异无统计学意义。结论吉西他滨联合奈达铂方案对晚期肺鳞癌的疗效与多西他赛联合顺铂方案相当,不良反应发生率低,安全性更高,值得进一步推广运用。
OBJECTIVE Patients with lung squamous carcinoma could not be diagnosed and treated in time because of few symptoms and signs. And lots of them would lose surgical indication. Therefore, chemotherapy is the major thera- py for those patients with the objectives of prolonging survival and improving life quality. In this study, we expect to ex- plore the clinic outcomes and safety of the combination of Gemcitabine and Nedaplatin in treating patients with advanced lung squamous carcinoma. METHODS A total of 184 patients with advanced lung squamous carcinoma in our hospital from October 10,2015 to December 9,2016 were involved in this study. Those patients were randomly divided into two groups, consisting of the observation group and the control group. Patients in the control group were treated by the com- bination of Docetaxel and Cisplatin, while those in the observation group were given the combination of Gemcitabine and Nedaplatin. All the patients were treated for at least 2 cycles. The clinical outcomes were evaluated after 2 cycles of treat- ment. And the side effects were assessed during the treatment. RESULTS There was no significant difference between the two groups in the short-term curative effect,χ2 =0. 113 ,P=0. 945. The total remission rate of the observation group and the control group were 40.22% （37/92） and 39.13% （32/92）, the difference was not statistically significant,χ2= 0. 023,P=0. 880. The control rate of the observation group and the control group were 65.22% （60/92） and 66.30% （61/92）, the difference was not statistically significant, χ2 = 0. 024, P = 0. 877. The incidence of leucocyte decline （χ2 = 31. 745,P〈0. 001） ,erythrocyte decline （χ2 =11. 280,P=0. 001） and nausea and vomiting （χ2=11. 290,P=0. 001） were significantly higher in the two groups （P〉 0. 05） , which were significantly lower than the control group,and the differ- ence was statistically significant （X2 =0. 035 ,P=0. 851）. Impaired liver function （χ2 =2. 421 ,P=0. 120）, impaired renal function （χ2 = 0. 464, P = 0. 496） and hair loss （χ2 = 1. 517, P = 0. 218） was not statistically significant. CONCLUSIONS The combination of Gemcitabine and Nedaplatin has similar short-term outcomes in patients with ad- vanced squamous carcinoma when compared to the combination of Docetaxel and Cisplatin. It has lower incidence of side effects and higher safety. Thus, it is worthy promoting in clinic.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2017年第15期1083-1086,共4页
Chinese Journal of Cancer Prevention and Treatment
关键词
肺鳞癌
吉西他滨
奈达铂
疗效
lung squamous carcinoma
gemcitabine
nedaplatin
clinic outcomes
